CN1410072A - Sulfadiazine silver chitinamine powder - Google Patents
Sulfadiazine silver chitinamine powder Download PDFInfo
- Publication number
- CN1410072A CN1410072A CN 02135792 CN02135792A CN1410072A CN 1410072 A CN1410072 A CN 1410072A CN 02135792 CN02135792 CN 02135792 CN 02135792 A CN02135792 A CN 02135792A CN 1410072 A CN1410072 A CN 1410072A
- Authority
- CN
- China
- Prior art keywords
- silver
- sulfadiazine
- chitinamine
- powder
- chitosan
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A medicine "Sulfapyrimidine silver-crustamine" in the dosage form of powder contains sulfapyrimidine silver (0.5-2 wt. portions), crustamine (1-50) and polyvinyl alcohol (50-150). Its advantages are high stability and antibacterial effect, and high wound-healing speed.
Description
Technical field
The present invention relates to the compound external used medicine technical field of silver sulfadiazine chitosan.
Background technology
Silver sulfadiazine (sulfadiazine silver) raw material is the crystalline powder of white or off-white color, and chance light or chance heat are perishable, and is all insoluble in water, ethanol, chloroform or ether.Often be used as the treatment of burn wound clinically with powder or ointment (cream).It not only can suppress traumatic infection, also can promote wound surface drying, incrustation and healing, and evident in efficacy, and the silver sulfadiazine has a broad antifungal spectrum is especially powerful to green pus bacterium inhibitory action, and astriction is still arranged, and is applicable to two degree or third degree burns, and is commonplace in clinical practice.But its existence is stable, antibacterial efficacy is relatively poor, to the slower shortcoming of the healing rate of wound surface.
Clinical research proves that chitosan promotes that wound healing effect is better.Chitosan contact and protection wound can form a skim; have good oxygen permeability, strong absorptive and slow enzyme (lysozyme) degradability etc.; it has following characteristics: one, good moisture-absorbing moisture-keeping function; keeping humidity of skin is the most basic condition that makes skin regeneration, and contains a plurality of hydrophilic group in the molecule of chitosan, and molecule space is big; can be in conjunction with a large amount of moisture content; water absorption, water-retaining property are all very strong, and have high viscosity, permeability and lubrication.Two, good anti-inflammation is arranged, kill the function of pathogenic bacterium, can prevent to produce dermatosis.Contain in the chitinous molecular structure amido (--NH2) group, it has bactericidal action, again the Acidity of Aikalinity of scalable skin surface.The normal pH value of blood is 7.3, is acid in case reduce, and then is pursued by countless ailments and afflictions.And chitinous pH value is 7.4, and just in time the tart body fluid pH value of adjustable band moves to alkalescence.Chitin can suppress or kill many harmful pathogen.Three, filming performance is good: chitosan dissolves in weak acid, CM-CT, and the CM-CTS water soluble forms viscous liquid.This liquid and skin, hair have stronger affinity and form film, and its film does not have rejection, and permeability is good, and is transparent, smooth, and can prevent dust, antistatic, easy cleaning, biodegradable, absorb.Four, have reproducibility, prevent skin oxidation and aging, chitin molecule, have amido (--NH2) group, can block the injury of radical pair Skin Cell, reduce the generation of lipid peroxide, reduce the deposition of pigment, it is white, healthy to help skin, the aging course of delaying skin.
Summary of the invention
The purpose of this invention is to provide a kind of sulfadiazine silver chitinamine powder, it can solve the stability that prior art exists and antibacterial efficacy is relatively poor, to the slower problem of the healing rate of wound surface.
The objective of the invention is to be achieved through the following technical solutions: sulfadiazine silver chitinamine powder, it comprises following component (in weight portion):
Silver sulfadiazine 0.5-2 chitosan 1-50
Polyvinyl alcohol 50-150
For further realizing also being achieved through the following technical solutions purpose of the present invention: described sulfadiazine silver chitinamine powder, it comprises following component (in weight portion):
Silver sulfadiazine 0.8-1.5 chitosan 2-30
Polyvinyl alcohol 70-130
Described sulfadiazine silver chitinamine powder, it comprises following component (in weight portion):
Silver sulfadiazine 0.9-1.2 chitosan 3-10
Polyvinyl alcohol 85-105
Described sulfadiazine silver chitinamine powder: it comprises following component (in weight portion):
Silver sulfadiazine 0.9-1.1 chitosan 4-6
Polyvinyl alcohol 90-100
Described sulfadiazine silver chitinamine powder, it comprises following component (in weight portion):
Silver sulfadiazine 1 chitosan 5
Polyvinyl alcohol 94
The beneficial effect that the present invention can produce: because of it passes through silver sulfadiazine and the scientific and reasonable prescription of chitosan, with the two and other adjuvant uniform mixing, and make micronization and pulverize, the silver sulfadiazine molecular energy is entrenched in the macromolecular material molecular structure, so improved the stability of silver sulfadiazine greatly, and the two prescription energy synergism, improve the antibacterial efficacy of silver sulfadiazine greatly, and can quicken the healing of wound surface.
The specific embodiment
Embodiment 1
Sulfadiazine silver chitinamine powder, it comprises following component (in weight portion):
Silver sulfadiazine 2Kg chitosan 50Kg
Polyvinyl alcohol 150Kg
The mixing pack after the known technology micronization is pulverized of above-mentioned prescription gets final product.
Embodiment 2
Described sulfadiazine silver chitinamine powder, it comprises following component (in weight portion):
Silver sulfadiazine 0.8Kg chitosan 2Kg
Polyvinyl alcohol 70Kg
The mixing pack after the known technology micronization is pulverized of above-mentioned prescription gets final product.
Embodiment 3
Described sulfadiazine silver chitinamine powder, it comprises following component (in weight portion):
Silver sulfadiazine 1.2Kg chitosan 10Kg
Polyvinyl alcohol 105Kg
The mixing pack after the known technology micronization is pulverized of above-mentioned prescription gets final product.
Embodiment 4
Described sulfadiazine silver chitinamine powder, it comprises following component (in weight portion):
Silver sulfadiazine 0.9Kg chitosan 4Kg
Polyvinyl alcohol 90Kg
The mixing pack after the known technology micronization is pulverized of above-mentioned prescription gets final product.
Embodiment 5
Described sulfadiazine silver chitinamine powder, it comprises following component (in weight portion):
Silver sulfadiazine 1Kg chitosan 5Kg
Polyvinyl alcohol 94Kg
The mixing pack after the known technology micronization is pulverized of above-mentioned prescription gets final product.
The technology that the present invention does not describe in detail partly is known technology.
Claims (5)
1, sulfadiazine silver chitinamine powder, it comprises following component (in weight portion):
Silver sulfadiazine 0.5-2 chitosan 1-50
Polyvinyl alcohol 50-150
2, sulfadiazine silver chitinamine powder according to claim 1 is characterized in that: it comprises following component (in weight portion):
Silver sulfadiazine 0.8-1.5 chitosan 2-30
Polyvinyl alcohol 70-130
3, sulfadiazine silver chitinamine powder according to claim 1 is characterized in that: it comprises following component (in weight portion):
Silver sulfadiazine 0.9-1.2 chitosan 3-10
Polyvinyl alcohol 85-105
4, sulfadiazine silver chitinamine powder according to claim 1 is characterized in that: it comprises following component (in weight portion):
Silver sulfadiazine 0.9-1.1 chitosan 4-6
Polyvinyl alcohol 90-100
5, sulfadiazine silver chitinamine powder according to claim 1 is characterized in that: it comprises following component (in weight portion):
Silver sulfadiazine 1 chitosan 5
Polyvinyl alcohol 94
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02135792 CN1410072A (en) | 2002-11-15 | 2002-11-15 | Sulfadiazine silver chitinamine powder |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02135792 CN1410072A (en) | 2002-11-15 | 2002-11-15 | Sulfadiazine silver chitinamine powder |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1410072A true CN1410072A (en) | 2003-04-16 |
Family
ID=4748361
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 02135792 Pending CN1410072A (en) | 2002-11-15 | 2002-11-15 | Sulfadiazine silver chitinamine powder |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1410072A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3087990A4 (en) * | 2013-12-24 | 2017-07-19 | Greenever | Gel-forming agent containing sulfonamide and chitosan and having a powdered dosage form |
| CN111166932A (en) * | 2020-02-29 | 2020-05-19 | 海南妙音春制药有限公司 | Liquid wound spray dressing and preparation method thereof |
-
2002
- 2002-11-15 CN CN 02135792 patent/CN1410072A/en active Pending
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3087990A4 (en) * | 2013-12-24 | 2017-07-19 | Greenever | Gel-forming agent containing sulfonamide and chitosan and having a powdered dosage form |
| US10172975B2 (en) | 2013-12-24 | 2019-01-08 | Greenever | Gel-forming agent comprising sulfa agent and chitosan agent and having powdered dosage form |
| CN111166932A (en) * | 2020-02-29 | 2020-05-19 | 海南妙音春制药有限公司 | Liquid wound spray dressing and preparation method thereof |
| CN111166932B (en) * | 2020-02-29 | 2021-01-26 | 海南妙音春制药有限公司 | Liquid wound spray dressing and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yuan et al. | Nano-silver functionalized polysaccharides as a platform for wound dressings: A review | |
| CN103463124A (en) | Bacterial cellulose/chitosan composite gel and preparation thereof, and application of composite gel in body surface wound surface healing | |
| US10226425B2 (en) | Pharmaceutical preparation and method of its production and use | |
| Wang et al. | Multifunctional effects of wound dressing based on chitosan-coordinated argentum with resistant bacterial penetration | |
| CN104740141B (en) | A kind of antimicrobial spray and preparation method thereof | |
| CN103083711A (en) | Chitosan-iodine composite biological medical film and preparation method thereof | |
| RU2485938C1 (en) | Gel-base for wound healing and cosmetic preparation and method of its obtaining | |
| CN1410072A (en) | Sulfadiazine silver chitinamine powder | |
| CN105833329A (en) | Hydrocolloid dressing and preparation method thereof | |
| CN108619550A (en) | A kind of hydrogel and preparation method thereof | |
| US11058712B2 (en) | Film for topical application in the treatment of skin lesions and method of obtaining and applying same | |
| CN112546282A (en) | Cationic polymer medical antibacterial dressing and preparation method thereof | |
| WO2016071405A2 (en) | Pharmaceutical preparation and method of its production and use | |
| CN116440317A (en) | Photothermal antibacterial hydrogel and preparation method thereof | |
| CN1442149A (en) | External use film forming powder for eliminating wound surface inflammation | |
| Talodthaisong et al. | A Shear‐Thinning, Self‐Healing, Dual‐Cross Linked Hydrogel Based on Gelatin/Vanillin/Fe3+/AGP‐AgNPs: Synthesis, Antibacterial, and Wound‐Healing Assessment | |
| CN1190196C (en) | Anti-inflammation antibiotic external used synthesized medicine, soluble hemostatic gauze and method for making the same | |
| Alibolandi et al. | Biopolymer-Based Hydrogel Wound Dressing | |
| CN116099035B (en) | Composite antibacterial hydrogel dressing and preparation method and application thereof | |
| CN117357692B (en) | In-situ curing forming hydrogel and preparation method and application thereof | |
| CN114984132B (en) | Wound spray capable of promoting coagulation and repair and preparation method thereof | |
| AU2019213007B2 (en) | Hydrophilic/hydrophobic pharmaceutical composition and method of its production and use | |
| WO2024139662A1 (en) | Composite antibacterial hydrogel dressing, preparation method therefor, and use thereof | |
| Deng et al. | Antioxidant and antibacterial hydrogel formed by protocatechualdehyde–ferric iron complex and aminopolysaccharide for infected wound healing | |
| Yu et al. | An adhesion-switchable hydrogel dressing for painless dressing removal without secondary damage |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |